• Team
  • Companies
  • About
  • Latest
  • Contact
  • Careers
  • Canaan Build
  • Talent Network
  • LP Portal
  • Resources
  • The WoVen Podcast
  • Canaan on Twitter
  • Canaan on LinkedIn

© Copyright 2025 Canaan | Legal

  • Team
  • Companies
  • About
  • Latest

Latest for IDEAYA Biosciences

A milestone in targeted oncology and looking ahead
Highlight

A milestone in targeted oncology and looking ahead

In honor of this historic event, we want to share a few thoughts about the future of targeted oncology and where we are making investments at Canaan.
BioCentury: With Ideaya deal, GSK bulks up synthetic lethality side of oncology business
Highlight

BioCentury: With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

A deal with Ideaya gives GSK a path to growing its synthetic lethality pipeline, a corner of the pharma’s cancer rebuild still primarily centered...
IDEAYA & the Next Frontier in Synthetic Lethality
Highlight

IDEAYA & the Next Frontier in Synthetic Lethality

WSJ: Ideaya Biosciences Collects $94 Million for Cancer Therapy
Activity

Fierce Biotech: Ideaya, Spelman College team up to provide young African American women a stepping stone to biotech careers

Activity

Endpoints News: Billions on the table, GSK’s Hal Barron antes $120M cash to partner with Ideaya

Activity

Fierce Biotech: GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Fierce 15 winner Ideaya

Activity

MedCity News: GSK pumps $120M into partnership with Ideaya in oncology precision medicine play

Activity

FierceBiotech: GV, Roche help Ideaya to $94M crossover round, setting stage for synthetic lethality, I-O trials

  • Canaan on Twitter
  • Canaan on LinkedIn
  • Contact
  • Careers
  • Canaan Build
  • Talent Network
  • LP Portal
  • Resources
  • The WoVen Podcast

© Copyright 2025 Canaan | Legal